| Jazz Pharmaceuticals, Inc. Announces Submission Of Complete Responses To FDA Approvable Letters For. |
|
|
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the submission of the complete response by Solvay Pharmaceuticals, Inc. to the FDA approvable letter for Luvox(R) CR (fluvoxamine maleate) extended-release capsules. The PDUFA action date is December 22, 2007. [click link for full article] Read more at: http://www.medicalnewstoday.com/articles/78670.php. |
| < Prev | Next > |
|---|
| Related Resources |
|---|
